NCT04713982

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

• Status: Active Not Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Examine the effects of deutetrabenazine on functional speech and gait impairment

Detailed description

This is a two-year, prospective, single-arm study examining the effects of deutetrabenazine on functional speech and gait impairment. Participants will undergo comprehensive evaluations of speech production, fine motor skills, gait, and balance both before and after the initiation of deutetrabenazine. The investigators will utilize a variety of standardized, well-validated assessments as well as 3D motion analysis of both speech and gait parameters to determine the functional impact of deutetrabenazine on speech and motor performance.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	Deutetrabenazine	Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor

Timeline

• Start date: 2021-11-19
• Primary completion: 2026-06-30
• Completion: 2026-10-01
• First posted: 2021-01-19
• Last updated: 2026-04-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study